Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Exclusion Criteria

• •Has any clinically significant abnormality identified in the screening physical examination, laboratory tests or electrocardiogram which, in the judgement of the investigator, would preclude safe completion of the study
• •Is female of childbearing potential
• •Has any of these cardiac conditions: uncontrollable or symptomatic arrhythmias, unstable angina, sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker), bradycardia (heart rate \<55 bpm), and stroke within three months of study screening, and history of myocardial infarction.
• •Has Congestive Heart Failure NYHA (New York Heart Association) class II-IV
• •Has type 1 diabetes mellitus
• •Has newly diagnosed type 2 diabetes (within 4 months of screening visit)
• •Has HbA1c \> 8.5%
• •Has the following, as it relates to subject's antidiabetic therapy:Initiated or changed dosage or formulation of thiazolidinediones (TZDs) within 6 months of screening visit.
• •A history of acute or chronic acidosis, including diabetic ketoacidosis
• •Has current clinical diagnosis of chronic obstructive pulmonary disease (COPD, e.g., chronic bronchitis) or asthma
• •Has a history of bronchospastic disease not undergoing active therapy in whom, in the investigator's opinion, treatment with study medication could provoke bronchospasm
• •Has evidence of any of the following clinically significant diseases that could impair the absorption, metabolism, or excretion of orally-administered medication:
• •renal disease defined as estimated Glomerular Filtration Rate (eGFR) \<60mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula below: GFR (mL/min/1.73m2) = 186 x \[Serum Creatinine (umol/L) x 0.0113\]-1.154 x Age(years)-0.203 (x 0.742 if female)
• •hepatic disease (i.e., ALT or AST levels greater than three times the upper limit of normal range, history of hepatic impairment, or by clinical assessment)
• •Chronic biliary disorders
• •Has endocrine disorders (e.g., pheochromocytoma, active and untreated hypo or hyperthyroidism)
• •Has any known contraindication to ACE inhibitors, alpha- or beta-blocker treatment
• •Has systemic disease, including cancer, with reduced (\<12 months) life expectancy
• •Has used an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
• •Has a history of a psychological illness or any condition that would interfere with the subject's ability to understand or complete the requirements of the study